Pharmerging Market, By Products (Pharmaceuticals, Healthcare and Others (IT and Record Management)), By Economy (Tier-1, Tier-2 and Tier-3), By Indication (Lifestyle Disease, Cancers & Autoimmune Diseases and Infectious Disease), By Distribution Channel (Hospitals, Clinics, Retail Pharmacies, E-Commerce and Drug Stores), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) - Trends, Analysis and Forecast till 2030

Report Code: PMI489422 | Publish Date: August 2023 | No. of Pages: 168

Pharmerging Market Companies

  • Sanofi S.A.
  • Pfizer Inc.
  • AstraZeneca Plc
  • GlaxoSmithKline Plc
  • F. Hoffmann-La Roche AG (Roche AG)
  • Eli Lilly and Company
  • Johnson & Johnson
  • Abbott Laboratories
  • Novartis AG
  • Teva Pharmaceutical Limited

Recent New:

  • In May 2024, AstraZeneca Plc introduced to construct a $1.five billion production facility in Singapore for antibody drug conjugates (ADCs), enhancing the worldwide deliver of its ADC portfolio. ADCs are next-era remedies that supply noticeably robust most cancers-killing sellers without delay to most cancers cells thru a focused antibody.
  • In April 2024, Pfizer Inc. introduced that it has acquired the U.S. Food and Drug Administration (FDA) acclaim for the supplemental Biologics License Application (sBLA), granting complete acclaim for TIVDAK (tisotumab vedotin-tftv) for the remedy of sufferers with recurrent or metastatic cervical most cancers with disorder development on or after chemotherapy.